Enwei Pharmaceutical Co., Ltd. (SHE:301331)

China · Delayed Price · Currency is CNY

21.23

-0.80 (-3.63%)

At close: Sep 10, 2026

Market Cap	2.24B -37.3%
Revenue (ttm)	826.13M -5.4%
Net Income	29.62M -48.8%
EPS	0.28 -51.1%
Shares Out	101.88M
PE Ratio	77.80
Forward PE	n/a
Dividend	0.66 (3.03%)
Ex-Dividend Date	May 28, 2026

Volume	1,306,149
Open	21.80
Previous Close	22.03
Day's Range	21.15 - 22.05
52-Week Range	18.87 - 35.80
Beta	0.58
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Enwei Pharmaceutical

Enwei Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of Chinese medicines and chemical drugs in China. The company offers drugs in the areas of gynecology, pediatrics, respiratory, stomatology, digestive, cardiovascular, hepatobiliary, and dermatology under the Jieeryin, Haowayou, and Likeshu brands. It also provides products for cold and fever relief, dental care, warming/nourishing/tonic purposes, and other uses; ointments, suppositories, capsules, effervescent tablets, and... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1986

Employees 1,501

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 301331

Full Company Profile

Financial Performance

In 2025, Enwei Pharmaceutical's revenue was 900.77 million, an increase of 10.91% compared to the previous year's 812.13 million. Earnings were 51.94 million, an increase of 38.53%.

Financial Statements